sunbet(中国)

专注给予质高价优

科学论文

Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for Cetuximab or TKI resistant cancer.
ESMO 2023
Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models.
ESMO 2023
Liu Z, Cao Y, Zhang L, et al. In-Depth Characterization of mAb Charge Variants by On-Line Multidimensional Liquid Chromatography-Mass Spectrometry. Anal Chem. 2023 May 23;95(20):7977-7984. doi: 10.1021/acs.analchem.3c00791. Epub 2023 May 12. PMID: 37170561.
Analytical Chemistry
Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: A randomized, double-blind,multicenter phase 3 study(ASTRUM-007).
ASCO 2023
First-line HLX07 Plus Serplulimab With or Without Chemotherapy Versus Serplulimab Plus Chemotherapy in Advanced/Recurrent Squamous Non-small Cell Lung Cancer: a Phase 2 study
ESMO Asia 2023
A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.
ASCO 2023

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97